Owners, management and financials
CVR: 39401975
Secondary names: Cell2Cure ApS
Previous names: Cell2Cure ApS
DKK -3,076,475
Gross profit
Net result: DKK -9,792,604
MEDIC ADVICE ApS (5-9,99%), Endeavour Cells ApS (50-66,65%)
3 more
CVR · view owners
Jens Kastrup, Annette Ekblond
2 more in management
Board: Anders Østergaard (chair) and 4 members
CVR · view management
Active
Founded 7 March 2018
CVR · view overview
5 employees
CVR · 2026
Name registered: Cell to Cure ApS
CVR · 07/07/2025
View the full event history
Cell to Cure ApS is a Danish company of the type Anpartsselskab based in Birkerød, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Cell2Cure ApS. The management consists of Jens Kastrup, Annette Ekblond and Mandana Haack-Sørensen. The board consists of Anders Østergaard (chair), Annette Ekblond, Jens Kastrup and Mandana Haack-Sørensen. The company's owners include MEDIC ADVICE ApS, Endeavour Cells ApS and Ekblond.ApS. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK -3,076,475 and a net result of DKK -9,792,604. Equity in the 2025 report amounted to DKK -1,179,103.
Selskabets formål er at drive virksomhed med handel, rådgivning og assistance inden for farmaceutisk og bioteknologisk industri og beslægtede brancher, samt anden dermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -3.1 mio. | -9.8 mio. | 9.6 mio. | -1.2 mio. | 12 | |
| 202301/09/2022 – 31/08/2023 | 100 t. | -1.5 mio. | 1.9 mio. | -1.9 mio. | 5 | |
| 202201/09/2021 – 31/08/2022 | 389 t. | -402 t. | 1.5 mio. | -366 t. | 5 | |
| 202101/09/2020 – 31/08/2021 | 295 t. | 218 t. | 1 mio. | 695 t. | 0 | |
| 202001/09/2019 – 31/08/2020 | 523 t. | 405 t. | 839 t. | 462 t. | 0 |
Compared to 1.039 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorThe CVR number of Cell to Cure ApS is 39401975.
The owners of Cell to Cure ApS include MEDIC ADVICE ApS, Endeavour Cells ApS and Ekblond.ApS.
The management of Cell to Cure ApS consists of Jens Kastrup, Annette Ekblond and Mandana Haack-Sørensen.
The board of Cell to Cure ApS consists of Anders Østergaard, Annette Ekblond and Jens Kastrup, with Anders Østergaard as chair.
In 2025, Cell to Cure ApS reported a gross profit of DKK -3,076,475.
Cell to Cure ApS had 5 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Cell to Cure ApS has published its annual report for 2025. Gross profit came to DKK -3,076,475, and the net result was DKK -9,792,604.
On July 7, 2025, the company changed its name from Cell2Cure ApS to Cell to Cure ApS.
Cell to Cure ApS has published its interim report for the period September 1, 2023 to December 31, 2024.
As of January 12, 2024, Jesper Kihl has left the board of directors of Cell to Cure ApS.
As of January 5, 2024, Anders Østergaard has joined the board of directors of Cell to Cure ApS.
As of January 5, 2024, Martin Roland Jensen has joined the board of directors of Cell to Cure ApS.
As of January 4, 2024, Martin Roland Jensen has left the board of directors of Cell to Cure ApS.
As of January 3, 2024, MEDIC ADVICE ApS is registered as an owner of Cell to Cure ApS with an ownership share of 5%.
As of January 3, 2024, Endeavour Cells ApS is registered as an owner of Cell to Cure ApS with an ownership share of 50%.
As of January 3, 2024, Ekblond.ApS is registered as an owner of Cell to Cure ApS with an ownership share of 10%.
As of January 3, 2024, JKastrup.ApS is registered as an owner of Cell to Cure ApS with an ownership share of 10%.
As of January 3, 2024, LMN.ApS is registered as an owner of Cell to Cure ApS with an ownership share of 10%.
Cell to Cure ApS has published its annual report for 2023. Gross profit came to DKK 100,337, and the net result was DKK -1,533,822.
Cell to Cure ApS has published its annual report for 2022. Gross profit came to DKK 389,024, and the net result was DKK -401,864.
As of December 13, 2022, Martin Roland Jensen has joined the board of directors of Cell to Cure ApS.
As of December 13, 2022, Annette Ekblond has joined the board of directors of Cell to Cure ApS.
As of December 13, 2022, Jens Kastrup has joined the board of directors of Cell to Cure ApS.
As of December 13, 2022, Mandana Haack-Sørensen has joined the board of directors of Cell to Cure ApS.
As of December 13, 2022, Jesper Kihl has joined the board of directors of Cell to Cure ApS.
As of March 11, 2022, Martin Roland Jensen is registered as director of Cell to Cure ApS.
Cell to Cure ApS has published its annual report for 2021. Gross profit came to DKK 294,954, and the net result was DKK 217,939.
Cell to Cure ApS has published its annual report for 2020. Gross profit came to DKK 523,178, and the net result was DKK 405,000.
Cell to Cure ApS has published its interim report for the period March 7, 2018 to August 31, 2019.
As of March 7, 2018, Annette Ekblond is registered as director of Cell to Cure ApS.
As of March 7, 2018, Jens Kastrup is registered as adm. dir. of Cell to Cure ApS.
As of March 7, 2018, Mandana Haack-Sørensen is registered as director of Cell to Cure ApS.
Cell to Cure ApS was founded on March 7, 2018.
Companies in the same industry and area
CVR 39389398
CVR 43067745
CVR 34040699
CVR 46418077
CVR 42067326
